Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 12, 2009, Pages 761-769

  Schutz H ^a   Fischer, R ^b   Grossmann M ^c   Mazur, D ^c   Leis, H J ^d   Ammer, R ^b  

^a BEBAC   (Austria)

^b Medice Arzneimittel Putter GmbH and Co KG   (Germany)

^c PAREXEL INTERNATIONAL   (United States)

^d BPA   (Austria)

Author keywords

Bioequivalence; Equasym Retard; Extended release; Medikinet retard; Methylphenidate

Indexed keywords

METHYLPHENIDATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 71849112238     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47761     Document Type: Article

References (25)

1. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen H-C, Sonuga-Barke EJS, Taylor E. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006; 15: 476-495.
2. Döpfner M, Banaschewski T, Schmidt J, Uebel H, Schmeck K, Gerber WD, Günther M, Knölker M, Gehrke M, Hässler F, Möhler E, Brünger M, Ose C, Fischer R, Poustka F, Lehmkuhl G, Rothenberger A. Long-acting methylphenidate preparation in children with ADHD - a multicenter study. Nervenheilkunde. 2003; 22: 85-92.
3. Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber G, Günther M, Hässler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. Comparative efficacy of once-a-day daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004; 13 (Suppl 1): I93-I101.
4. EMEA Human Medicines Evaluation Unit, CHMP Efficacy Working Party, Therapeutic Subgroup on Pharmacokinetics. Questions & Answers on the Bioavailability and Bioequivalence Guideline. EMEA/CHMP/EWP/40326/ 2006. (27 July 2006).
5. Eurand Inc. Diffucaps (online). http://www.eurand.com/ Technologies/Controlling-Drug-Release/Diffucaps/Vandalia: Eurand; accessed April 21, 2009.
6. Fischer R, Schütz H, Grossmann M, Leis HJ, Ammer R. Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on apple-sauce. Int J Clin Pharmacol Ther. 2006; 44: 135-141.
7. Haessler F, Tracik F, Dietrich H, Stammer H, Klatt J. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther. 2008; 46: 466-476.
8. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharm Ther Toxicol. 1990; 28: 72-78.
9. Hauschke D, Steinijans V, Pigeot I. Bioequivalence studies in drug development. Hoboken:Wiley; 2007, 20-23.
10. Leis HJ, Fauler G, Raspotnig G, Windischhofer W. Negative ion chemical ionization for the determination of methylphenidate in human plasma by stable isotope dilution gas chromatography/mass spectrometry. J Mass Spectrom. 2000; 35: 1100-1104.
11. Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003; 42: 393-401.
12. MEDICE Arzneimittel Pütter GmbH & Co. KG. Zusammenfassung derMerkmale des Arzneimittels (Summary of Product Characteristics): Medikinet retard 10 mg/20 mg/30 mg/40 mg. Iserlohn: Medice; 2006.
13. Midha KK, McKay G, Rawson MJ, Korchinski ED, Hubbard JW. Effects of food on the pharmacokinetics of methylphenidate. Pharm Res. 2001; 18: 1185-1189.
14. Modi NB, Wang B, Noveck RJ, Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol. 2000; 40: 1141-1149.
15. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24-month outcomes of treatment strategies for attention deficit/hyperactivity disorder. Pediatrics. 2004; 113: 754-761.
16. National Institutes of Health. National Institutes of Health consensus development conference statement: diagnosis and treatment of attention deficit/hyperactivity disorder. Hum Psychopharmacol. 2000; 12: 527-546.
17. Patrick KS, Mueller RA, Gualtieri CT, Breese GR. Pharmacokinetics and actions of methylphenidate. In: Meltzer HY. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987, 1387-1395.
18. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2009, ISBN 3-900051-07-0, http://www.R-project.org.
19. Rochdi M, González MA, Hirshey Dirksen SJ. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int J Clin Pharmacol Ther. 2004; 42: 285-292.
20. Swanson J, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2003; 60: 204-211.
21. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Stehli Nguyen A, Decory HH, Hirshey Dirksen SJ, Hatch SJ and the COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics. 2004; 113: 206-216.
22. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A. EU Clinical Guidelines for hyperkinetic disorder, first update. Eur Child Adolesc Psychiatry. 2004; 13 (Suppl 1): I7-I30.
23. Tuerck D, Wang Y, Maboudian M, Wang Y, Sedek G, Pommier F, Appel-Dingemanse S. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethylphenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther. 2007; 45: 662-668.
24. UCB GmbH. Fachinformation (Zusammenfassung der Merkmale der Arzneimittel; Summary of Product Characteristics): Equasym retard 10/20/ 30 mg. Monheim: UCB; 2006.
25. Wang Y, Lee L, Somma R, ThompsonG, Bakhtiar R, Lee J, Singh Rekhi G, Lau H, Sedek G, Hossain M. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Biopharm Drug Dispos. 2004; 25: 91-98.